SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

Gitlab is trending following its earnings report, which showed a beat on Q4 revenue and non-GAAP EPS but delivered weaker-than-expected forward guidance. This has ignited a fierce debate in the community, with concerns over slowing growth and AI competition clashing against arguments for the company's strong fundamentals, buyback program, and AI integration tailwinds.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is generating strong community buzz, frequently discussed as a multi-chain meme coin with an organic, decentralized approach and a deflationary burning mechanism, further fueled by its growing presence on platforms like Coinbase and Base.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending at multi-year highs amid intense anticipation for its pivotal Phase 3 REGAL trial results for GPS in AML, with strong community conviction in a groundbreaking outcome driving discussions of a potential buyout and a significant short squeeze.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending amidst community debate over its persistently delayed earnings report date and a recently retracted Pentagon listing linking it to China's military. While many view the stock as oversold and undervalued with promising AI advancements, others remain cautious of ongoing geopolitical and regulatory uncertainties impacting the Chinese tech giant.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing significant momentum after its strong Q4 earnings highlighted robust growth in USDC circulation and on-chain transaction volume, with the community actively discussing its pivotal role as a foundational payment standard for AI agentic commerce, driving its rally as a key stablecoin infrastructure play.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to significant market volatility, as investors weigh strong fundamental tailwinds from soaring AI-driven memory demand and recent analyst upgrades against broader market contagion from geopolitical tensions impacting major South Korean chip competitors. This has created a polarized discussion, with bulls viewing the dip as a prime buying opportunity given Micron's robust HBM sales and upcoming earnings, while bears anticipate further correction amidst macro fears and profit-taking.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF (EWY) is plummeting and experiencing market halts amid escalating Middle East tensions and surging oil prices, fueling widespread fear selling and deleveraging in what many describe as a "crowded retail trade." Conversely, some community members are actively discussing this as a strong "buy the dip" opportunity, citing resilient fundamentals for its key memory/AI chip holdings like Samsung and SK Hynix.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending amid intense community debate, as a puzzling sell-off starkly contrasts with soaring crude oil prices and escalating Middle East tensions, prompting discussion of market manipulation, dilution, or a significant shakeout before a potential rally.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as escalating Middle East tensions, including Iran's threats to the Strait of Hormuz, spark concerns over global oil supply and trigger a sharp sell-off across Asian markets, heavily impacting the semiconductor sector. Despite international market turmoil, traders are debating the Nasdaq's unusual intraday resilience, questioning if it can withstand geopolitical pressures or if a deeper correction is imminent.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is hitting new highs, driven by stellar January revenue growth and its 2nm capacity being fully booked by top-tier clients, solidifying its indispensable role in the AI chip supercycle. The community widely views the company as the foundational "picks and shovels" leader despite persistent geopolitical uncertainties.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Femasys (NASDAQ:FEMY) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Femasys from a "sell" rating to a "hold" rating in a research note on Friday...

<ul class="summary-bullets"><li>The stake sale comes on the heels of the company increasing its stake in TNF Pharmaceuticals in September by an additional $3 million.&nbsp;</li><li>PharmaCyte said that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.&nbsp;</li><li>The company said that monetizing its stake in Femasys will help strengthen its financial position.</li></ul> PharmaCyte Biotech, Inc. (PMCB) said on Tuesday that it sold its stake in Femasys Inc. (FEMY), thereby increasing its cash and marketable securities to about $20 million.The company had cash and marketable securities of only about $13.3 million as of the end of July. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.pharmacyte.com/press-releases/detail/319/pharmacyte-biotech-successfully-monetizes-femasys-stake">said</a> that monetizing its stake in Femasys will help strengthen its financial position.Shares of <a href="https://stocktwits.com/symbol/PMCB">PMCB </a>traded 25% higher at the time of writing.<h2 class="st-heading-2">PharmaCyte’s Financial Position</h2>CEO Josh Silverman stated that the successful monetization of the Femasys position demonstrates the effectiveness of the strategic and disciplined capital allocation approach. “We are committed to deploying shareholder capital intelligently, balancing near-term returns with opportunities that can deliver sustained value creation,” he said.Overall, PharmaCyte now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash. The company highlighted its low stock price below $1 and added that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.The stake sale comes on the heels of the company increasing its stake in Q/C Technologies, formerly known as TNF Pharmaceuticals, in September by an additional $3 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PMCB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that the news shows the company has ways to generate cash without doing share offerings.<stembedurl>https://stocktwits.com/MadBat/message/637404061</stembedurl>Another expects the stock to cross the $1 threshold.<stembedurl>https://stocktwits.com/cbt2020/message/637412358</stembedurl>PMCB stock fell 48% this year and by about 53% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-slips-after-q4-revenue-guidance-disappoints/cL52NcEREgI">Nio Stock Slips After Q4 Revenue Guidance Disappoints</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

PMCB Stock Jumps 25% After Company Sells Stake In Femasys

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.

Equity

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.


<ul class="summary-bullets"><li>Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.</li><li>The company raised $12 million through convertible notes, with potential total proceeds of $58 million if all warrants are exercised, strengthening its balance sheet.</li><li>Retail investors on Stocktwits turned bullish on the news, calling Femasys a long-term play with disruptive potential in women’s health.</li></ul>Retail chatter around Femasys spiked on Monday following the company’s announcement that it secured U.S. Food and Drug Administration (FDA) approval to advance the final phase of its pivotal trial for FemBloc, a non-surgical permanent birth control device, and raised $12 million in financing that could grow to $58 million if all warrants are exercised.<h2 class="st-heading-2">FDA Clears Final Phase Of FemBloc Trial</h2>Femasys announced FDA approval to resume enrollment for the final phase of the FemBloc pivotal FINALE trial, allowing it to move closer to U.S. Pre-Market Approval (PMA).The Investigational Device Exemption (IDE) approval came following the successful completion of the trial’s first stage, advancing the commercialization of the world’s first non-surgical, permanent birth control in the U.S.FemBloc uses a polymer-based delivery system that blocks the fallopian tubes without incisions or anesthesia, offering a safer and lower-cost alternative to surgical sterilization.<h2 class="st-heading-2">Financing Deal With Potential Upside To $58 Million</h2>Alongside the FDA update, Femasys entered into a private placement agreement with institutional and accredited investors, led by Jorey Chernett, to issue $12 million in senior secured convertible notes and warrants,&nbsp;with the potential to raise total proceeds to $58 million if exercised for cash.The company said proceeds will go toward refinancing debt and advancing&nbsp;the commercialization of its fertility and permanent birth control portfolio.The notes carry an 8.5% annual interest rate and are convertible at $0.73 per share, a 15% premium to the stock’s prior closing price. Warrants carry exercise prices between $0.81 and $1.10 per share, with 10-year terms.<h2 class="st-heading-2">Stocktwits Users Cheer Regulatory Win</h2>On Stocktwits, retail sentiment for Femasys was ‘bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:969/142;" src="https://news.stocktwits-cdn.com/femy_ss_jpg_e7ab6d375e.webp" alt="femy ss.jpg" width="969" height="142"><figcaption>FEMY sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user said they viewed Femasys as a long-term play, describing its regulatory progress and disruptive women’s health products as strong growth drivers. The user added that the company’s performance is likely to move “based on fundamentals” rather than hype, noting that women’s health remains an underappreciated sector.<stembedurl>https://stocktwits.com/CoconutNinja/message/634760377</stembedurl>Another user speculated whether the stock would see after-hours upside following the positive news.<stembedurl>https://stocktwits.com/steve04240/message/634739416</stembedurl><a href="https://stocktwits.com/symbol/FEMY">Femasys’ stock</a> has declined 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Femasys logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing

Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Femasys (FEMY) delivered earnings and revenue surprises of +11.11% and -48.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Femasys Inc. (FEMY) traded 17% lower on Friday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/30/3091024/0/en/Femasys-Announces-Pricing-of-Underwritten-Public-Offering-and-Concurrent-Private-Placement-with-Gross-Proceeds-of-4-5-Million.html">announced</a> the pricing of an underwritten public offering of 3.6 million shares of its common stock at $0.85 per share.The offer price represents a discount of about 17% from the stock’s closing price on Thursday.The company also announced a separate concurrent private placement of approximately 1.7 million shares of its common stock at the same price as sold to certain existing institutional stockholders of Femasys, as well as a price of $1.02 per share to certain of its directors and officers.The gross proceeds of the public offering and private placement to Femasys are expected to be about $4.5 million.The company stated that it intends to use the net proceeds for the expansion of its commercial efforts, the development of its products and product candidates, general corporate purposes, capital expenditures, working capital, and general and administrative expenses.Both the public offering and the private placement are expected to close on or about June 2 and are subject to the successful completion of customary closing conditions.On Stocktwits, the retail sentiment around Femasys jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_8_59_37_AM_png_3daa1e0a3d.webp" alt="FEMY's Sentiment Meter and Message Volume as of 9:00 a.m. ET on May 30, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>FEMY's Sentiment Meter and Message Volume as of 9:00 a.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the company and said they will buy shares in the short term.<stembedurl>https://stocktwits.com/Mirto/message/616299906</stembedurl>Another user, however, expressed concerns about the stock falling below $1.<stembedurl>https://stocktwits.com/goldenxb/message/616299012</stembedurl><a href="https://stocktwits.com/symbol/FEMY">FEMY stock</a> is down by over 23% this year and by about 28% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-dell-to-build-doe-s-doudna-supercomputer/ch0MD6bRbuG">Nvidia, Dell To Build DOE’s Doudna Supercomputer – ‘Time Machine for Science,’ Says Jensen Huang</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up

The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Shares of Femasys Inc. (FEMY) tumbled nearly 14% on Thursday after the company’s 2024 <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.femasys.com/news/news-details/2025/Femasys-Announces-Financial-Results-for-Year-Ended-December-31-2024-and-Provides-Corporate-Update/default.aspx">earnings</a> fell below Wall Street estimates.The company reported a 52% jump in annual sales to $1.62 million compared to 2023, but failed to meet an analyst estimate of $2.71 million, according to FinChat data.The loss per share of $0.85, though lower than the $0.93 reported in 2023, exceeded an estimated loss of $0.80.The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.Femasys said its current cash and cash equivalents, which includes approximately $5.4 million raised subsequent to year-end, will be sufficient to fund its ongoing operations into third quarter of 2025.The company focuses on addressing critical unmet needs in women’s health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products.Femasys CEO Kathy Lee-Sepsick said that the company is focused on commercializing FemaSeed, its first-line infertility treatment, and expects U.S. revenue to increase by about 50% in the first quarter of 2025 compared to the previous quarter.“We are continuing to advance our FemBloc to commercialization in Europe while executing on the clinical pivotal trial for U.S. FDA approval,” she added. FemBloc is the company's non-surgical permanent birth control.On Stocktwits, retail investor sentiment about Femasys dropped slightly in the ‘bullish’ territory (56/100) while message volume dropped from ‘high’ to ‘normal’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:651/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_1_54_06_PM_png_ca980a7546.webp" alt="FEMY's Sentiment Meter and Message Volume as of 2:05 p.m. ET on March 27, 2025 | Source: Stocktwits" width="651" height="151"><figcaption>FEMY's Sentiment Meter and Message Volume as of 2:05 p.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user noted the company’s increase in annual sales and opined that the company is “heading in the right direction for sure.”<stembedurl>https://stocktwits.com/stoneblood/message/609410856</stembedurl>Another user highlighted they were buying the stock.<stembedurl>https://stocktwits.com/Mirto/message/609411502</stembedurl><a href="https://stocktwits.com/symbol/FEMY">FEMY shares</a> have gained over 19% this year but have lost nearly 11% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/microalgo-stock-surges-after-wimi-hologram-cloud-expands-stake/chJ2ah6RbEB">MicroAlgo Stock Surges After WiMi Hologram Cloud Expands Stake, Locking In Shares For 10 Years – Retail Hopes For Another Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic

The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

FEMY
Femasys Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FEMY News

FEMYFemasys Inc